Abbott Laboratories (ABT)

Oncology Corporate Profile

Stock Performance

43.8300
-0.0500

HQ Location

100 Abbott Park Road
Abbott Park, IL 60064

Company Description

Abbott Laboratories is a global, broad-based healthcare company devoted to discovering new medicines, new technology and new ways to manage health. Abbott operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.

Website: http://www.abbott.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ABT-869multiple tyrosine kinase inhibitor1st line metastatic Breast cancerIIGenentech / Roche
ABT-869multiple tyrosine kinase inhibitor1st line metastatic Chronic Myelogenous Leukemia (CML)IIGenentech / Roche
ABT-869multiple tyrosine kinase inhibitor1st line metastatic Non Small Cell Lung Cancer (NSCLC)IIGenentech / Roche
ABT-869multiple tyrosine kinase inhibitor1st line metastatic Renal cell carcinoma (RCC)IIGenentech / Roche
ABT-263/RG7433Bcl-2 inhibitor2nd line metastatic Chronic Lymphocytic Leukemia (CLL)II
ABT-869multiple tyrosine kinase inhibitorHepatocellular carcinoma (HCC)IIGenentech / Roche
ABT-869multiple tyrosine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)IGenentech / Roche
ABT-263/RG7433Bcl-2 inhibitorNon-Hodgkin's Lymphoma (NHL)I
ABT-263/RG7433Bcl-2 inhibitorSmall Cell Lung Cancer (SCLC)I

Source: http://www.abbott.com

Recent News Headlines

Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML

10/12/2016 11:29 am

(NASDAQ) Oct 12, 2016 - Companion diagnostic technology to be utilized with enasidenib (AG-221/CC-90007) and AG-120 development programs for relapsed/refractory acute myeloid leukemia (AML); approximately 20% of AML patients have an IDH mutation.

Abbott Wins FDA Nod For Absorb Stent

7/5/2016 12:06 pm

(Mass Device) July 5, 2016 - Abbott said today it won FDA premarket approval for its Absorb bioresorbable everolimus eluting heart stent, touting it as the 1st fully dissolving stent approved for treating coronary artery disease.

Cancer Patients Miss Appointments, Prescriptions Due To Inability To Afford Care

6/6/2016 02:02 pm

(UNC Health Care) June 3, 2016 - More than one-in-four cancer patients had to pay more for medical care than they could afford, according to a study led by UNC Lineberger member Stacie Dusetzina, PhD. A reported 18 percent were unable to afford their prescription medications.

Abbott Laboratories to Buy St. Jude Medical for $25 Billion

4/28/2016 12:23 pm

(USA Today) Apr 28, 2016 - Health care giant Abbott Laboratories has reached a deal to acquire medical device maker St. Jude Medical in a cash-and-stock deal valued at $25 billion.

Abbott Test Cleared by FDA as Companion Dx for CLL Drug

4/14/2016 11:26 am

(GenomeWeb News) Apr 13, 2016 – Abbott announced today that the US Food and Drug Administration has granted premarket approved for the company's Vysis CLL FISH Probe Kit as a companion diagnostic for AbbVie and Genentech's newly approved chronic lymphocytic leukemia (CLL) drug Venclexta (venetoclax).

McKesson Falls After Saying It Will Cut 1,600 Jobs in U.S.

3/17/2016 11:05 am

(Bloomberg) Mar 16, 2016 - McKesson Corp. shares fell after the drug distributor said Wednesday night that it will fire 1,600 people, or about 4 percent of its U.S. workforce, to cut costs after losing some key customers.

Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest

2/1/2016 11:52 am

(Bloomberg) Feb 1, 2016 - Abbott Laboratories agreed to buy Alere Inc. for $56 a share, or about $5.8 billion, to become the leader in the market for rapid medical tests and adding another deal to a long list in the fast-consolidating medical devices and technology space.

Pfizer Gets EU Green Light for Hospira Merger

8/5/2015 12:03 pm

(Morningstar/Dow Jones Newswires) Aug 4, 2015 - Pfizer Inc. received a green light from European Union regulators Tuesday for its $16 billion acquisition of smaller rival Hospira Inc. after agreeing to make divestments designed to guard against price rises and protect the research and development of drugs.

CDC: Coordinated Approach Could Cut Projected ‘Superbug’ Infections In Half

8/5/2015 12:03 pm

(Washington Post) Aug 4, 2015 - A new report looks at infections from four of the deadliest pathogens, including C. diff. and MRSA.

FDA Drug Safety Communication: FDA Warns About Cases Of Rare Brain Infection With Ms Drug Gilenya (fingolimod) in Two Patients With No Prior Exposure To Immunosuppressant Drugs

8/5/2015 12:03 pm

(FDA.gov) Aug 4, 2015 - The U.S. Food and Drug Administration is warning that a case of definite progressive multifocal leukoencephalopathy (PML) and a case of probable PML have been reported in patients taking Gilenya (fingolimod) for multiple sclerosis (MS).

FDA Says It's Impossible to Completely Clean Dirty Scopes

8/5/2015 12:03 pm

(NBCNews.com/Associated Press) Aug 5, 2015 - Federal health officials laid out extra safety measures hospitals can take to clean specialized medical scopes linked to sometimes deadly bacterial outbreaks across the U.S.

assistPoint.com Web Site Launched

8/5/2015 12:02 pm

(Benzinga) Aug 4, 2015 - assistPoint Partners, LLC is proud to announce a revolutionary technology platform that uses Cloud innovation to consolidate oncology patient assistance programs.

Dr. Rakesh Rohatgi Merges His Practice With Florida Cancer Specialists & Research Institute

8/5/2015 12:01 pm

(FCS) Aug 3, 2015 - Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Rakesh Rohatgi, MD, is merging his practice (Tri-County Hematology & Oncology) with Florida Cancer Specialists.

Cancer Survival 'Lagging In England’

8/5/2015 12:01 pm

(BBC News) Aug 5, 2015 - England's track record for cancer survival remains poorer than other countries with similar health systems, a study suggests.

Surrogate Endpoints May Not Predict OS In Oncology Clinical Trials

8/5/2015 12:00 pm

(Healio) Aug 4, 2015 - A majority of trial-level validation studies of surrogate endpoints demonstrated little correlation with survival rates, according to a systematic review of trial-level meta-analyses.

Biocept Launches its First Liquid Biopsy Diagnostic Test for Colorectal Cancer

8/5/2015 12:00 pm

(StreetInsider) Aug 5, 2015 - New test uses patient’s blood sample to detect KRAS, predictive biomarker for solid tumor cancers.

The International Myeloma Foundation (IMF) Announces Publication of New Diagnostic Guidelines to Better Assess Patients and Guide Treatment

8/5/2015 12:00 pm

(IMF) Aug 5, 2015 - The International Myeloma Foundation (IMF) announced the publication of newly revised guidelines for the International Staging System that are used to assess progression of myeloma in new patients and determine the proper course of treatment.

European Group Issues Updated Treatment Guidelines for Mesothelioma

8/5/2015 12:00 pm

(Surviving Mesothelioma) Aug 3, 2015 - A group of medical researchers has just released an updated set of clinical practice guidelines for treating patients with malignant pleural mesothelioma, one of the rarest and most treatment-resistant forms of cancer.

Lehigh Valley Health Network to Join Memorial Sloan Kettering Cancer Alliance

8/5/2015 12:00 pm

(MSK) Aug 4, 2015 - Memorial Sloan Kettering Cancer Center (MSK) and Lehigh Valley Health Network (LVHN) announced today the beginning of a unique and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and highest-caliber cancer care.

Real-Time Data for Cancer Therapy

8/5/2015 11:05 am

(MIT News) Aug 4, 2015 - Biochemical sensor implanted at initial biopsy could allow doctors to better monitor and adjust cancer treatments.

Contrary to Popular Myth, 'The Pill' Prevents Womb Cancer, Study Finds

8/5/2015 11:05 am

(Reuters) Aug 4, 2015 - Using an oral contraceptive, often referred to as "the pill", gives long-term protection against womb cancer and the longer it is used the greater the reduction in risk, scientists said on Wednesday.

MedImmune and Mirati Therapeutics Partner On Immuno-Oncology Combination In Lung Cancer

8/5/2015 11:05 am

(AstraZeneca) Aug 5, 2015 - AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.

Amgen Reports Positive Preliminary Results on Leukemia Drug

7/17/2015 11:02 am

(Reuters) July 16, 2015 - Amgen Inc on Thursday said some patients with a deadly form of leukemia experienced complete remission after being treated with its Blincyto drug in a midstage clinical trial, results that could eventually lead to an expanded approval of the pricy cancer medicine.

Eli Lilly Wins UK Alimta Drug Patent Case on Appeal, Shares Jump

6/25/2015 12:03 pm

(Reuters) June 25, 2015 - Eli Lilly has won a patent case in the Court of Appeal in London over its blockbuster Alimta lung cancer drug, boosting prospects for future sales and dealing a blow to generic challenger Actavis, now renamed Allergan.

Abbott OKs Ousting Planned Parenthood From Cancer Program

6/22/2015 11:26 am

(The Texas Tribune) June 20, 2015 - A months-long effort to keep Republicans from pushing Planned Parenthood out of a state cancer screening program for low-income women ended in defeat on Saturday when Republican Gov. Greg Abbott signed off on the proposal.

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

4/20/2015 11:04 am

(Merck) Apr 19, 2015 - Merck, known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer (NSCLC).

Abbott Inks Exclusive Licensing Deal With Institut Curie For Bladder Cancer Biomarker

1/15/2015 11:56 am

(GenomeWeb) Jan 14, 2015 - Abbott today announced that it has signed an exclusive licensing agreement with the Institut Curie for a biomarker for bladder cancer.

Multiple Myeloma Research Foundation Announces New Data From CoMMpass Study™ Is Now Available For Public Access on the Researcher Gateway

12/5/2014 11:04 am

(MMRF) Dec 4, 2014 - Unique public access to patient-level biomarker and clinical data from landmark longitudinal study of people diagnosed with multiple myeloma.

Abbott, AbbVie Win Dismissal of Claims Over Humira, AndroGel

9/26/2014 12:29 pm

(Reuters) Sept 25, 2014 - A federal judge in Chicago dismissed racketeering claims in a lawsuit accusing Abbott Laboratories and AbbVie Inc of causing health plans to pay unnecessarily for the latter's blockbuster Humira arthritis drug and AndroGel testosterone drug instead of cheaper generics.

Sanofi Talked With Abbott, Mylan on Mature Products Sale

7/16/2014 12:14 pm

(Bloomberg) July 16, 2014 - Sanofi held talks with Mylan Inc., Abbott Laboratories, and private-equity firms including Warburg Pincus LLC about a possible sale of a mature-products portfolio, according to an internal document.

Sanofi Talked With Abbott, Mylan on Mature Products Sale

7/16/2014 07:01 am

(Bloomberg) July 16, 2014 - Sanofi held talks with Mylan Inc., Abbott Laboratories, and private-equity firms including Warburg Pincus LLC about a possible sale of a mature-products portfolio, according to an internal document.

Mylan Gets 100 Brands, Big Sales Force Outside U.S. in Deal with Abbott

7/14/2014 12:21 pm

(Pittsburgh Business Times) July 14, 2014 - What will Mylan Inc. get out of its acquisition of the non-U.S. generic pharmaceutical division of Abbott?

Mylan Gets 100 Brands, Big Sales Force Outside U.S. in Deal with Abbott

7/14/2014 07:02 am

(Pittsburgh Business Times) July 14, 2014 - What will Mylan Inc. get out of its acquisition of the non-U.S. generic pharmaceutical division of Abbott?

Older Breast Cancer Patients Do Follow Drug Therapy: Study

6/17/2014 07:00 am

(Drugs.com/HealthDay News) June 16, 2014 - Many older breast cancer patients with localized disease are taking drug treatments to prevent their cancer from returning, a new study finds.

AstraZeneca Spends $190 Mln on New UK Cancer Drug Factory

11/11/2013 12:00 pm

(Reuters) Nov 11, 2013 - AstraZeneca said on Monday it would invest 120 million pounds ($190 million) in a new facility at its global manufacturing site in Macclesfield, northern England, to continue production of prostate cancer drug Zoladex.